The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Leukemia recurrence necessitates novel immunotherapies.
• Cancer vaccines, particularly personalized ones, are emerging as a promising treatment strategy.
• Investigating the mechanism of action for oncolytic virus-infected cell vaccines (ICVs) is crucial.

Purpose of the Study:

• To elucidate the mechanism by which ICVs induce anti-tumor immunity.
• To determine the role of the immunoproteasome (ImP) in ICV efficacy.
• To assess the impact of viral variants on ICV effectiveness.

Main Methods:

• Utilized the L1210 murine leukemia model.
• Created ICVs by infecting and irradiating leukemia cells.
• Employed CRISPR-Cas9 gene editing to generate knockout cell lines for mechanistic studies.

Main Results:

• Pro-inflammatory interferons induced by infected cells activate the immunoproteasome (ImP).
• Vaccines using oncolytic vesicular stomatitis virus (oVSV) showed complete protection, while wild-type virus was less effective.
• ImP-knockout cells did not alter treatment efficacy, indicating ImP is not essential.

Conclusions:

• Immunoproteasome (ImP) expression by vaccine cells is not a requirement for the efficacy of leukemia ICVs.
• The study provides insights into the immunomodulatory mechanisms of oncolytic virus-based cancer vaccines.
• Further research may explore other pathways contributing to ICV-mediated anti-tumor immunity.